Characteristic | Patient 1 | Patient 2 | Patient 3 | Patient 4 |
Age (y) | 77 | 74 | 44 | 74 |
Sex | F | M | F | F |
Diagnosis | Neuroendocrine carcinoma (bladder) | Neuroendocrine tumor (lung) | Neuroendocrine tumor (ileum) | Neuroendocrine tumor (ileum) |
Tumor grade | G3 | G1 | G2 | G2 |
First diagnosed | 5 mo ago | 3 y ago | 5 y ago | 11 mo ago |
Pretreatment evaluation | ||||
ECOG performance status | 2 | 0 | 1 | 0 |
Remission status* | PD | PD | PD | PD |
Chronic kidney disease† | Grade 3 | Grade 3 | Grade 2 | Grade 3 |
Three-mo follow-up | ||||
ECOG performance status | 2 | 0 | 0 | 0 |
Remission status* | Mixed response | PR | SD | PR |
Chronic kidney disease† | Grade 3 | Grade 3 | Grade 2 | Grade 3 |
Adverse events‡ | ||||
Anemia (reversible) | Grade 2 | Grade 1 | Grade 2 | Grade 2 |
Leukopenia (reversible) | Grade 2 | Grade 1 | Grade 2 | Grade 0 |
Thrombocytopenia (reversible) | Grade 0 | Grade 3 | Grade 0 | Grade 0 |
Maximum follow-up (mo) | 15 | 12 | 13 | 12 |
Remission status† | PD | PR | SD | PR |
↵* Response was assessed with CT according to the Response Evaluation Criteria in Solid Tumors, version 1.1.
↵† Chronic kidney disease was graded according to the guidelines of the National Kidney Foundation.
↵‡ Adverse events were graded according to the Common Terminology Criteria for Adverse Events, version 4.0, of the National Cancer Institute.
ECOG = Eastern Cooperative Oncology Group; PD = progressive disease; PR = partial response; SD = stable disease.